Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 15/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.40 |
| ▸ | CHRNG | P07510 | 1/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.40 |
| ▸ | CHRND | Q07001 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19443285 | 1.00 | TACR2 (0.41) | TACR2TSHRCHRNA1CHRNGCHRNB1 | |
| SCHEMBL22476555 | 0.84 | TACR2 (0.40) | TACR2GAA | |
| SCHEMBL21781844 | 0.84 | MMP2 (0.42) | TACR2TSHR | |
| SCHEMBL16645016 | 0.84 | REN (0.42) | TSHRCHRNA1CHRNGCHRNB1CHRND | |
| SCHEMBL19647312 | 0.84 | GAA (0.54) | TSHRGAA | |
| SCHEMBL18912329 | 0.84 | GAA (0.54) | TSHRGAA | |
| SCHEMBL20750962 | 0.83 | GAA (0.41) | TACR2TSHRRENGAA | |
| SCHEMBL20862029 | 0.83 | TACR2 (0.38) | TACR2TSHRCHRNA1CHRNGCHRNB1 | |
| SCHEMBL22810961 | 0.83 | POLB (0.49) | GAA | |
| SCHEMBL21699252 | 0.83 | POLB (0.49) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772971-B2 | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates | Mersana Therpeutics, Inc. (US) | 2020-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772971-B2 | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates | PBRM1, BRAP, STAMBP | TACR2 2234/4885TSHR 4578/4885CHRNA1 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.